X4 Pharmaceuticals

Zenas

This biopharmaceutical company develops and commercialises immunology-based therapies for patients with autoimmune diseases and rare fibroinflammatory conditions.

Ultragenyx

This biopharmaceutical company develops and commercialises therapies for patients with serious rare and ultra-rare genetic diseases.

Immusoft

This clinical-stage biotechnology company develops engineered B cell therapies to treat patients suffering from rare inherited metabolic disorders and other chronic diseases.

SpringWorks Therapeutics

This biopharmaceutical company develops and commercialises targeted oncology medicines and therapies for patients with rare diseases and cancer.

Imara

This biopharmaceutical company develops oral small-molecule therapies to treat patients with rare genetic blood disorders, including sickle cell disease and beta thalassemia.

Deciphera Pharmaceuticals

This biopharmaceutical company develops and commercialises kinase-inhibiting drugs for patients with cancer, immunological diseases, and neurological conditions.

PHVS

This company develops oral therapies to treat and prevent hereditary angioedema attacks for patients with rare diseases.

Immunic Therapeutics

The company develops oral therapies for chronic inflammatory and autoimmune diseases for patients with neurological and gastrointestinal conditions.